Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia
Clinical trial NCT04325737 · COMPLETED
Trial details
- NCT number
- NCT04325737
- Sponsor
- Sumitomo Pharma Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-31
- Primary completion
- 2020-08-07
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.